Valproic Acid

Introduction Overview

Generic Name

Valproic acid

Brand Name

Depakene, Depacon, Stavzor

Dosage Form

Intravenous solution, oral capsule, oral liquid

Drug Class

Fatty acid derivative anticonvulsants

Pharmacokinetics

Absorption:
Valproic acid is well absorbed following oral administration, with bioavailability approaching 100%. It can be administered as oral capsules, liquids, or intravenous formulations. Peak plasma concentrations are usually reached within 1 to 4 hours after oral dosing. The absorption rate may be influenced by the formulation and whether the medication is taken with food; taking valproic acid with food can reduce gastrointestinal upset but may slightly delay absorption. Valproic acid does not undergo significant first-pass metabolism, contributing to its high oral bioavailability.

Distribution:
Valproic acid exhibits extensive distribution throughout body tissues and fluids, with an apparent volume of distribution ranging between 0.1 to 0.4 L/kg. It is approximately 90-95% bound to plasma proteins, primarily albumin, and this binding is concentration-dependent and saturable. At higher plasma concentrations, protein binding decreases, leading to an increased free (active) drug fraction. This property is clinically significant in patients with hypoalbuminemia or those receiving concomitant medications that can displace valproic acid from binding sites, potentially increasing toxicity.

Metabolism:
Valproic acid is extensively metabolized in the liver through multiple pathways. The primary metabolic routes include glucuronidation by uridine 5'-diphospho-glucuronosyltransferase (UGT) enzymes and mitochondrial beta-oxidation. Cytochrome P450-mediated oxidation is a minor pathway. Besides the major metabolites resulting from conjugation and beta-oxidation, valproic acid metabolism produces several minor metabolites, some of which are implicated in hepatotoxicity. The metabolic clearance of valproic acid can be influenced by factors such as age, liver function, and concomitant drugs which can inhibit or induce the metabolic enzymes. Genetic mitochondrial disorders can alter metabolism and increase the risk of toxicity.

Elimination:
Valproic acid and its metabolites are mainly eliminated via renal excretion. The parent drug is minimally excreted unchanged in urine (<3% of the dose). The elimination half-life ranges widely, typically between 9 to 16 hours in healthy adults but can vary with age and hepatic function. In children, clearance is generally higher, resulting in shorter half-lives. Renal impairment can affect the elimination of valproic acid metabolites, necessitating dosage adjustments. Due to its saturable protein binding and nonlinear kinetics at higher doses, monitoring plasma concentrations is essential to avoid toxicity, especially during dosage changes or in specific populations such as the elderly or those with hepatic dysfunction.

Dosage Forms

Available Dosage Forms:
- Intravenous solution: 100 mg/mL
- Oral capsules: 250 mg
- Oral liquid (syrup): 250 mg/5 mL

Dosages for Adults and Adolescents:
For seizure disorders and bipolar disorder, initial dosing typically starts at 10-15 mg/kg/day divided into 2-3 doses, with gradual titration up to 60 mg/kg/day as needed for clinical effect. For migraine prophylaxis, lower doses may be used, titrated to effect and tolerability. The maximum recommended dose generally does not exceed 60 mg/kg/day. Dosage adjustments should be individualized based on clinical response and plasma valproic acid concentrations. Frequent monitoring is necessary to ensure therapeutic levels between 50-100 mcg/mL, keeping in mind the active free fraction.

Specific Patient Populations:
- Pediatric patients under 2 years require cautious use due to increased risk of hepatotoxicity and mitochondrial disease sensitivity; dosing and monitoring should be more stringent.
- Elderly patients may require dose adjustments owing to altered pharmacokinetics and increased susceptibility to sedation and hepatotoxicity.
- Patients with hepatic impairment should use valproic acid cautiously with close monitoring of liver enzymes and plasma concentrations.
- Patients with urea cycle disorders or mitochondrial diseases such as Alpers-Huttenlocher syndrome are contraindicated due to risk of fatal hepatotoxicity.
- Pregnancy demands careful risk-benefit assessment, and doses may need adjustment with monitoring due to altered pharmacokinetics and fetal risk.

Clinical guidelines emphasize tailored dosing regimens incorporating both clinical response and periodic plasma concentration assessments, with careful consideration for drug interactions and patient-specific factors.

Mechanism Of Action

Valproic acid exerts its anticonvulsant and mood-stabilizing effects primarily through multiple complementary mechanisms acting on neuronal signaling pathways. One of the main molecular actions is the enhancement of gamma-aminobutyric acid (GABA) neurotransmission. Valproic acid increases brain levels of GABA, an inhibitory neurotransmitter, by inhibiting GABA transaminase and succinic semialdehyde dehydrogenase, enzymes responsible for GABA degradation. This elevation of GABA levels enhances inhibitory synaptic transmission, stabilizing neuronal excitability and reducing seizure likelihood.

At the cellular level, valproic acid modulates voltage-gated sodium channels by prolonging their inactive state, which decreases high-frequency neuronal firing associated with seizure activity. It also influences T-type calcium channels, reducing low-threshold calcium currents that contribute to absence seizures. Additionally, valproic acid may affect potassium channel conductance, which further stabilizes neuronal membranes against hyperexcitability.

Biochemically, valproic acid acts as a histone deacetylase (HDAC) inhibitor, influencing gene expression by promoting chromatin remodeling and transcriptional activation. This epigenetic modulation may contribute to its mood-stabilizing properties and neuroprotective effects observed in bipolar disorder and other neuropsychiatric conditions. Research suggests that HDAC inhibition by valproic acid can enhance expression of neurotrophic factors such as brain-derived neurotrophic factor (BDNF), promoting neuronal survival and plasticity.

Clinically, the multimodal mechanism of valproic acid confers a broad spectrum of efficacy across generalized and partial seizures, bipolar disorder manic episodes, and migraine prophylaxis. Its combined enhancement of inhibitory neurotransmission, modulation of excitatory ion channels, and epigenetic effects distinguishes it from other anticonvulsants such as carbamazepine or phenytoin, which predominantly act via sodium channel blockade alone. Extensive clinical trials support these mechanisms correlating with improved seizure control and mood stabilization, while ongoing research explores valproic acid’s neuroprotective roles and potential novel indications.

Pharmacological Actions

Enhances central nervous system inhibitory neurotransmission via increased GABA levels.
Inhibits voltage-gated sodium channels, reducing neuronal excitability and seizure propagation.
Modulates T-type calcium channels, effective in treating absence seizures.
Acts as a histone deacetylase (HDAC) inhibitor, influencing gene expression and providing neuroprotective effects.
Stabilizes neuronal membranes, reducing abnormal electrical activity.
Exerts mood-stabilizing effects beneficial in bipolar disorder management.
Provides prophylactic efficacy in migraine prevention through modulation of neuronal excitability.
Exhibits antiepileptic properties against a broad spectrum of seizure types including generalized and partial seizures.
Demonstrates sedative and calming effects due to CNS depressant activity.
Induces expression of neurotrophic factors aiding in neuronal health and plasticity.

Therapeutic Or Clinical Uses

Treatment of various seizure disorders including generalized, absence, and partial seizures.
Management of manic episodes related to bipolar disorder.
Prophylaxis of migraine headaches.
Adjunctive therapy in epilepsy when monotherapy is insufficient.
Potential off-label uses in psychiatric and neurological conditions requiring mood stabilization.
Prevention of recurrent seizures in patients with epilepsy.
Management of cluster headache prophylaxis.
Used in treatment protocols for complex regional pain syndrome and neuropathic pain in some clinical settings.
Investigated for neuroprotective roles in neurodegenerative diseases.
Management of agitation and mood dysregulation in certain neuropsychiatric disorders.

Side Or Adverse Effects

Nausea, vomiting, and gastrointestinal discomfort including diarrhea and abdominal pain.
Dizziness, drowsiness, and general CNS sedation leading to fatigue or weakness.
Tremors and ataxia with impaired coordination and unsteady gait.
Visual disturbances including blurred or double vision.
Hair loss (alopecia) and changes in hair texture.
Weight gain and alterations in appetite.
Hepatotoxicity which may result in fatal liver failure, especially in young children and mitochondrial disorders.
Pancreatitis presenting with abdominal pain, nausea, and vomiting.
Rare but serious hypersensitivity reactions including rash, fever, and organ involvement.
Hematologic effects such as thrombocytopenia, easy bruising, or bleeding tendencies.
Mood changes including depression, irritability, agitation, and suicidal ideation.
Confusion, cognitive impairment or changes in mental status.
Hyperammonemia leading to encephalopathy and lethargy.
Drowsiness and sedation, with increased risk in elderly populations.
Potential teratogenicity leading to neural tube defects and cognitive impairment in exposed fetuses.

Precautions

Monitor liver function tests regularly due to risk of hepatotoxicity.
Use caution in patients with a history of liver disease or mitochondrial disorders.
Avoid abrupt discontinuation to prevent rebound seizures; taper dosage gradually under medical supervision.
Monitor blood counts regularly for hematologic side effects.
Assess mental health status periodically to detect mood or behavioral changes, including suicidal thoughts.
Dose adjustments may be necessary in elderly patients or those with renal or hepatic impairment.
Use effective contraception in women of childbearing potential due to teratogenic risks.
Avoid use in pregnancy unless benefits outweigh risks; not recommended for migraine prophylaxis during pregnancy.
Monitor valproic acid plasma concentrations especially when used with interacting drugs or during dosage changes.
Be alert for signs of pancreatitis and discontinue drug immediately if suspected.
Educate patients to avoid alcohol consumption while on therapy.
Evaluate for potential drug interactions before initiating valproic acid.
Consider special caution in pediatric patients under 2 years due to increased toxicity risk.
Inform patients about signs of serious adverse effects such as rash, jaundice, or unusual fatigue.
Provide counseling on the importance of adherence to dosing schedule and follow-up.

Warnings

Valproic acid can cause fatal liver failure, particularly in children under 2 years and persons with mitochondrial disorders.
Contraindicated in patients with known liver disease, urea cycle disorders, and Alpers-Huttenlocher syndrome.
Teratogenic effects including neural tube defects and impaired cognitive development; not to be used for migraine prevention during pregnancy.
Risk of pancreatitis that may be life-threatening; discontinue immediately if pancreatitis is suspected.
Do not discontinue suddenly to avoid life-threatening seizures; dose tapering is required.
Potential for severe skin reactions and hypersensitivity affecting multiple organ systems.
Use with caution in patients with depression or suicidal ideation; monitor mood changes closely.
Interaction with hormonal contraceptives may reduce seizure control; inform about contraceptive efficacy.
Avoid concomitant use with other hepatotoxic drugs or in patients with impaired hepatic function.
Increased sedation and drowsiness risks in elderly patients; evaluate functional status regularly.
Monitor ammonia levels in patients with unexplained encephalopathy.
Risk of hyperammonemic encephalopathy even without significant liver dysfunction.
Valproic acid passes into breast milk; breastfeeding is generally not recommended during therapy.
Potential for blood dyscrasias; monitor blood cell counts routinely.
Emergency medical attention required if symptoms of allergic reaction, severe rash, or jaundice occur.

Contraindication

Known hypersensitivity to valproic acid or any formulation components.
Active liver disease or significant hepatic dysfunction.
Urea cycle disorders due to risk of hyperammonemia and encephalopathy.
Genetic mitochondrial disorders such as Alpers-Huttenlocher syndrome, particularly in children under 2 years.
Pregnancy when used for migraine prophylaxis due to teratogenic risk.
Patients with a history of pancreatitis related to valproic acid use.
Severe thrombocytopenia or other significant hematologic abnormalities caused by previous valproic acid therapy.
Concomitant use of other drugs that cause fatal hepatotoxicity or mitochondrial toxicity without close monitoring.
Severe hypersensitivity reaction history to valproic acid or related compounds.
Use in patients unable to comply with monitoring requirements or who have poor adherence risking toxicity.

Drug Interactions

May increase plasma concentrations and toxicity of other anticonvulsants like phenobarbital, phenytoin, and carbamazepine.
Interaction with lamotrigine increasing risk of serious skin reactions.
Estrogen-containing hormonal contraceptives can reduce valproic acid levels, decreasing seizure control.
Valproic acid can displace highly protein-bound drugs (e.g., warfarin) increasing free drug levels and risk of bleeding.
Concomitant use with aspirin may increase free valproic acid concentrations by protein displacement.
Enzyme inhibitors like cimetidine reduce valproic acid metabolism, increasing plasma levels.
Simultaneous use with topiramate may increase risk of hyperammonemia.
Interactions with carbapenem antibiotics can reduce valproic acid serum levels drastically.
Risk of additive CNS depression when combined with alcohol, benzodiazepines, or other sedatives.
Valproic acid inhibits metabolism of drugs like zidovudine, potentially increasing toxicity.
Co-administration with lamotrigine requires careful dose adjustment and monitoring for skin rash.
May alter clotting parameters and enhance anticoagulant effects when used with warfarin.
Interactions with statins and potential increased risk of myopathy.
Use caution with drugs affecting hepatic enzyme systems that metabolize valproic acid.
Herbal products such as St. John’s Wort may reduce effectiveness of valproic acid.

Preparations Of The Drug

Valproic acid intravenous solution 100 mg/mL for administration by infusion.
Oral capsule formulations containing 250 mg valproic acid.
Oral liquid (syrup) preparations containing 250 mg valproic acid per 5 mL.
Extended-release formulations available under various brand names depending on region.
Combination products with other anticonvulsants in some markets.
Generic formulations widely available, facilitating cost-effective therapy.
Specific dosage forms designed to optimize absorption and minimize gastrointestinal upset.
Unit-dose packaging includes bottles for liquids and blister packaging for capsules.
Specialized measuring devices recommended for accurate dosing of oral liquids.
Intravenous dosage forms intended for hospital or clinical use under supervision.
Storage instructions: store at room temperature away from moisture and heat.
Patient information leaflets provided with all preparations highlighting important safety and administration details.
Capsules are not to be crushed or chewed to maintain proper release profiles.
Availability of formulations for pediatric and adult dosing requirements.
Shelf life and stability information as per manufacturing and regulatory guidelines.